Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Absci Corp reported a net loss for the third quarter of 2026 and continues to incur significant losses as it funds its Integrated Drug Creation platform and internal drug programs. As of October 30, 2026, the company had 172,745,810 shares of common stock outstanding and indicated a need for additional capital to fund future operations and clinical development.
Absci Corp reported third quarter 2026 financial results and provided updates on its generative AI-designed therapeutic pipeline. The company is on track to release interim proof-of-concept data for its ABS-201 program in pattern hair loss in December 2026 and plans to initiate a Phase 2 trial for endometriosis in mid-2027.
“As we approach our first look at proof-of-concept data for ABS-201 next month, followed by full data early next year, we are excited for the opportunity to potentially demonstrate our program's ability to stimulate hair regrowth in a convenient and durable way.”
Sean McClain, Founder and CEO
“As ABS-201 progresses through the clinic, we have begun building our commercial infrastructure to support this and potential future programs. In line with that strategy, we are thrilled to be welcoming Gerry Muhle to Absci as our Chief Commercial Officer, whose experience we believe will position ABS-201 and our expanding program pipeline for success.”
Kardigan, Inc. is a clinical-stage biopharmaceutical company focusing on cardiovascular diseases with lead candidates Danicamtiv, Ataciguat, and Tonlamarsen. As of November 2026, the company is an emerging growth company with 93,597,398 shares of common stock outstanding and continues to anticipate significant financial losses as it funds its clinical trials and Prolaio platform development.
Data I/O Corporation reported Q3 2026 revenues of $4.9 million and highlighted the October completion of its $23 million acquisition of V-TEK, Inc. and A&J Programming. The company secured $13.25 million in direct investment and a $7.5 million credit line to fund the transformational deal, which is expected to double revenues and diversify the business into AI, photonics, and robotics markets.
Term
Q3 2026
“The most important measure of our recent performance and our prospects for the future is the completion of the transformational acquisition of V-TEK.”
William Wentworth, President and CEO of Data I/O Corporation
“The NEW Data I/O has become a reality. With the V-TEK acquisition, our expanded products and services now address multibillion-dollar markets. The NEW Data I/O serves industries such as data centers, AI, photonics, industrial automation, robotics, medical, military, aerospace and defense, significantly reducing our reliance on automotive.”
William Wentworth, President and CEO of Data I/O Corporation
Pelthos Therapeutics reported Q3 2026 financial results, highlighted by Zelsuvmi net product revenue of $15.2 million, a 114% increase year-over-year. The company also highlighted its pending transformative merger with Castle Creek Biosciences, which was announced in October 2026 to create a diversified biotechnology company focused on skin diseases.
“Zelsuvmi delivered another solid quarter, generating net product revenue of $15.2 million. Thousands of patients have already benefited from Zelsuvmi and we remain focused on driving Zelsuvmi growth and building on our success with the planned launches of Xepi® targeted in the first quarter of 2027 and Xeglyze® targeted in the third quarter of 2027.”
Scott Plesha, CEO of Pelthos
“In October, after the close of the third quarter, we took an important step in our pursuit of long-term value by announcing our agreement to combine with Castle Creek, a transaction that we believe will create a stronger, more diversified biotechnology company.”
Octave Intelligence reported a significant net loss of $1.86 billion for the nine months ended September 30, 2026, primarily driven by a $2.15 billion 'other operating expense' which includes a substantial goodwill impairment. Despite the bottom-line loss, total revenue grew slightly to $1.20 billion for the nine-month period, supported by a 6% increase in subscription revenue.
BK Technologies reported a net income of $9.67 million for the first nine months of 2026, driven by an 8.3% increase in sales to $69.99 million. The company's cash position strengthened significantly to $29.16 million, despite increased engineering and product development expenses and a $3.0 million investment in a convertible note receivable.
Charlotte’s Web reported Q3 2026 financial results, highlighting its lowest operating loss since 2019 despite a revenue decline. The company attributed the revenue pressure to new full-spectrum hemp restrictions in California and a strategic reduction in deep discounting to improve margins. Management is currently navigating evolving federal hemp policy and negotiating potential pilot programs with healthcare organizations for 2027.
Term
Q3 2026
“Third-quarter revenue primarily reflected the restrictions on the sale of full-spectrum hemp products in California that took effect in July. We have since reintroduced broad-spectrum products in California and sales have steadily begun to recover there. Nationally, we have sharply reduced deep discounting so that our pricing reflects the premium quality and reliable efficacy customers expect from Charlotte’s Web. That lowered revenue in the near term, but it also improved margins and helped deliver our smallest operating loss since 2019.”
Bill Morachnick, Chief Executive Officer of Charlotte’s Web
Applied Aerospace & Defense reported record third-quarter 2026 revenue of $182.1 million, a 48.6% increase year-over-year, driven by strong demand in space and defense end markets. The company generated net income of $30.6 million and grew its contract backlog to nearly $1.3 billion, providing significant multi-year revenue visibility.
Term
Q3 2026
“Our third quarter reflected broad-based demand across our end markets. We delivered record revenue of $182.1 million and Adjusted EBITDA of $39.7 million. Excluding acquisitions completed in 2026, revenue grew 20.3%, while those acquisitions added capabilities and capacity in areas that matter most to our customers.”
Trip Ferguson, Chief Executive Officer of Applied
“What distinguishes Applied is the diversity of our growth. Space and launch systems, defense aviation and airborne systems, and advanced sensing and precision strike systems each delivered double-digit revenue growth, while backlog increased to nearly $1.3 billion across the portfolio.”
Parabilis Medicines reported third-quarter 2026 financial results, ending the period with $1.1 billion in cash and marketable securities. The company reached alignment with the FDA on the Phase 3 registrational trial design for zolucatetide in desmoid tumors, with initiation planned for the first half of 2027. Additionally, the company entered a clinical collaboration with Revolution Medicines to evaluate zolucatetide in combination therapies for metastatic colorectal cancer.
Term
Q3 2026
“With each successive clinical update, we are building a stronger foundation for zolucatetide as a unique medicine with the potential to make a meaningful difference for patients across multiple diseases.”
Mathai Mammen, M.D., Ph.D., Chairman, Chief Executive Officer and President
“The progress across our portfolio continues to strengthen our conviction in the ability of our Helicon platform to repeatedly translate breakthrough science into medicines that can meaningfully improve patients’ lives.”
Mathai Mammen, M.D., Ph.D., Chairman, Chief Executive Officer and President
Yarrow Bioscience reported third quarter 2026 financial results, ending the period with $268.9 million in cash following a $172.5 million public offering. The company is currently enrolling patients in its Phase 2a/2b DIRECTION-GD trial for YB-101, with topline data expected in the second half of 2027.
“We made significant progress in the third quarter, including dosing our first patient in the Phase 2a portion of the DIRECTION-GD trial and strengthening our balance sheet through the completion of our merger and subsequent public offering. The financing extends our expected cash runway into 2030 and positions us to advance YB-101 in Graves’ disease and prepare for our next steps in thyroid eye disease.”
Rebecca V. Frey, PharmD, President and Chief Executive Officer
Octave Intelligence reported Q3 2026 financial results with total revenue of $415 million and net income of $59 million. The company also announced that its Board of Directors approved a new $200 million share repurchase program, reflecting confidence in its recurring revenue strategy and free cash flow growth.
“Our third quarter results were in line with our expectations, and we remain on track to achieve our outlook for the full year. ARR grew 7% over the prior year to $1.17 billion, and SaaS revenue grew 18%, as we continue our focused shift toward recurring revenue. Product innovation and go-to-market improvements continued to gain traction this quarter, and we’re carrying that momentum into the fourth quarter”
Mattias Stenberg, Chief Executive Officer
“Additionally, our Board of Directors recently approved a $200 million share repurchase program, a decision that reflects its confidence in our company strategy, medium-term financial targets, and ability to grow free cash flow.”
Century Therapeutics reported a total asset increase to $262.6 million as of September 30, 2026, driven by a significant increase in common stock issuance and long-term investments. The company's accumulated deficit grew to $871.6 million, reflecting ongoing development costs for its iPSC-derived immune cell therapies.
Ftai Infrastructure CEO and President Kenneth J. Nicholson Buys $1.53M of Stock
Kenneth J. Nicholson, CEO and President, bought 400,000 shares of Ftai Infrastructure Inc. at $3.83 a share, worth $1.53M in total on Nov 10, 2026. Shares held after the trade: 2,575,539 (+18.4%).
Generate Biomedicines, Inc. is a clinical-stage biotechnology company utilizing its AI-driven 'Generate Platform' for drug discovery. As of October 29, 2026, the company had 129,096,666 shares of common stock outstanding and is classified as an emerging growth company and a non-accelerated filer.
Standard Nuclear, Inc. reported a significant revenue increase to $11.3 million for the first nine months of 2026, driven by new product revenue, though it maintained a net loss of $24.2 million. The company successfully completed an IPO and a 2-for-1 stock split, ending the period with a substantially strengthened cash position of $223.1 million.
Cyngn Inc. reported its Q3 2026 financial results, highlighting year-to-date revenue of $405.5 thousand and a cash position of $34.9 million with no debt. The company noted commercial progress including a follow-on order from a Fortune 100 heavy equipment manufacturer and the launch of its DriveMod EasyLaunch program to lower adoption barriers for autonomous industrial vehicles.
EyePoint reported Q3 2026 financial results and announced a strategic prioritization of its DURAVYU Phase 3 program in Diabetic Macular Edema (DME). The company expects this prioritization to generate $30 million in annualized savings following mixed Phase 3 results in wet AMD.
“The recent Phase 3 wet AMD data demonstrated DURAVYU’s ability to control fluid and maintain retinal anatomy through Week 56, along with a favorable safety profile that included every six-month redosing. This important data supports our strategic decision to prioritize our resources on DME, where we believe there is strong scientific and clinical rationale for DURAVYU as a durable treatment option for this vision threatening exudative disease.”
Jay S. Duker, M.D., President and Chief Executive Officer of EyePoint
Jose A. Fernandez stepped down as Co-Chief Operating Officer of StepStone Group Inc. effective November 11, 2026, though he will remain with the firm as a Partner. Consequently, Jason P. Ment ceased to serve as Co-COO but will continue as President, with corporate operational functions now overseen by CEO Scott W. Hart and Mr. Ment.
Mobility Global Inc. completed its separation from S&P Global on July 1, 2026, becoming an independent publicly traded company. For the nine months ended September 30, 2026, the company reported revenue of $1,401 million and net income of $150 million, compared to $1,304 million and $194 million in the prior year period, respectively.
Alkermes entered into a settlement and license agreement with Teva Pharmaceuticals to resolve a patent infringement lawsuit regarding LYBALVI. Under the agreement, Teva is granted a non-exclusive, royalty-free license to market its generic version of the drug in the U.S. starting in November 2039, or May 2040 if pediatric exclusivity is obtained.
Mobility Global reported its first full quarter as a standalone public company, with revenue increasing 7.4% year-over-year to $478 million. The company reported net income of $42 million and adjusted EBITDA of $195 million, while also authorizing a new $800 million share repurchase program.
Term
Q3 2026
“Our first full quarter as a standalone public company was a solid one, with growth stepping up from the first half across both segments. We are bringing our CARFAX and B2B businesses together as One Mobility Global and applying AI to our proprietary data, trusted brands and deeply embedded customer relationships to deliver more value to our customers and drive growth.”
Bill Eager, Chief Executive Officer of Mobility Global
For the quarter ended September 30, 2026, NIQ Global Intelligence reported revenues of $1,119.1 million and net income attributable to NIQ of $35.8 million, a significant improvement from the $198.6 million loss in the prior year period. The company's balance sheet shows $572.6 million in cash and total debt of approximately $3.55 billion as of the end of the third quarter.
BK Technologies reported record third-quarter revenue of $25.3 million, driven by strong federal demand and the adoption of its BKR 5000 Orange radio by the U.S. Forest Service. The company achieved a gross margin of 50.7% and grew its cash position to $29.2 million with no debt. Additionally, the company doubled its share repurchase authorization to $10 million and made a $3.0 million strategic investment in software provider Tango Tango.
Term
Q3 2026
“Our third quarter results underscore the durability of our business model and demonstrate our ability to consistently deliver profitable growth. Federal demand was a key growth driver leading to record third quarter revenue of $25.3 million, a gross margin above 50% and an increase in net income of 9% that outpaced revenue growth.”
Kardigan, Inc. reported third quarter 2026 financial results, ending the period with $591.4 million in cash to fund operations through 2027. The company achieved significant clinical milestones, including completing enrollment in the Phase 2b portion of its danicamtiv KINSHIP-DCM trial and the Phase 2b KATALYST-AV trial for ataciguat. Topline data for the danicamtiv trial is expected in the second quarter of 2027.
Term
Q3 2026
“We made meaningful progress this quarter in advancing our portfolio of late-stage cardiovascular programs for people who urgently need better treatment options. Completing enrollment in the Phase 2b portion of our Phase 2b/3 adaptive KINSHIP-DCM trial is a significant milestone for danicamtiv and for people with genetic dilated cardiomyopathy.”
Tassos Gianakakos, co-founder, chief executive officer and board chair
BCP Investment Corp reported total investment income of $34.8 million for the nine months ended September 30, 2026, compared to $31.1 million in the prior year period. The company's Net Asset Value (NAV) per share decreased to $13.13 from $16.68 at year-end 2025, while total assets declined to $449.5 million as the company manages its portfolio and prepares for a potential merger with Investcorp Credit Management BDC, Inc.
Kiora Pharmaceuticals reported third quarter 2026 financial results and highlighted the strategic in-licensing of KIO-401, a late-stage oral neuroprotective asset for retinal diseases. The company ended the quarter with $16.3 million in cash and is preparing for a Phase 3 registration trial for KIO-401 in patients with Central Retinal Artery Occlusion (CRAO).
“The addition of KIO-401 transforms Kiora into a late-stage retinal therapeutics company. We are building on the significant amount of CMC, non-clinical and clinical data that already exists on KIO-401 through Senju’s previous and ongoing efforts. With exclusive rights outside Asia, we are preparing for a single, phase 3, registration trial of KIO-401 in patients across the United States, Europe and other territories.”
Brian M. Strem, Ph.D., President and Chief Executive Officer
NIQ Global Intelligence reported Q3 2026 financial results, achieving positive GAAP EPS for the first time since its IPO with revenue of $1.12 billion. The company also announced a new $150 million share repurchase program and raised its full-year 2026 guidance following six consecutive quarters of exceeding targets.
“Q3 was a milestone quarter — we exceeded the top end of our guidance across all key metrics for the sixth consecutive quarter, delivered positive GAAP earnings per share for the first time since our IPO, and reached our net leverage milestone a quarter ahead of plan.”
Jim Peck, Executive Chairman and Chief Executive Officer
Rockwell Medical reported net sales of $19.1 million for Q3 2026, a 20% increase over the prior year, though net loss widened to $2.3 million. The company maintained a cash and investment position of $22.5 million while managing a total accumulated deficit of $408.1 million.
RCM Technologies reported net income of $11.5 million for the thirty-nine weeks ended October 3, 2026, an increase from $10.2 million in the prior year period. Revenue grew to $250.3 million compared to $232.9 million, while the company continued its share repurchase program, increasing treasury stock to $91.4 million.